glp-1 next generation Retatrutide. The evolution. A next-generation triple agonist designed to advance metabolic research through GLP-1, GIP, and glucagon receptor pathways. Supporting innovation through trusted peptide sourcing. For healthcare professionals. Research GLP-1, GIP & GLP-3 for

Weekly subcutaneous injection Tirzepatide activates both GLP-1 and GIP receptors, producing larger average weight loss than semaglutide in head-to-head trials

Foss JD, Wainford RD, Engeland WC, Fink GD, Osborn JW

By using B12 instead of just corticosteroids, patients benefit from reduced side effects without compromising effective pain relief

Medicare recipients who meet the eligibility requirements will have to pay a $50 monthly copay to access the GLP-1 drugs

Semaglutide and Body Composition Data from the STEP trials indicates that approximately 39% of weight lost with semaglutide comes from lean mass, with the remainder from fat mass